View Older Stories View More Recent Stories

Aug 9, 2022 07:00AM Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Aug 9, 2022 07:00AM Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
Aug 8, 2022 05:22PM Cybin Announces Up to USD$35 Million At-The-Market Equity Program
Aug 8, 2022 05:22PM CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
Aug 8, 2022 04:10PM View Announces Q2 Earnings, Reaffirms 2022 Guidance and Provides Update on Financing; Dynamic Glass Investment Tax Credit included in the Climate package of the Senate Passed Inflation Reduction Act
Aug 8, 2022 04:10PM View Announces Q2 Earnings, Reaffirms 2022 Guidance and Provides Update on Financing; Dynamic Glass Investment Tax Credit included in the Climate package of the Senate Passed Inflation Reduction Act
Aug 8, 2022 04:05PM Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 8, 2022 04:02PM Aytu BioScience (AYTU) Announces Public Offering
Aug 8, 2022 04:01PM Aytu BioPharma Announces Launch of Public Offering
Aug 8, 2022 07:05AM uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Aug 5, 2022 06:31PM Wall St Week Ahead: Inflation data may seal fate of unloved U.S. stock rally
Aug 4, 2022 04:05PM Orchid Island Capital Announces Second Quarter 2022 Results
Aug 4, 2022 08:01AM Poseida Therapeutics (PSTX) Prices 20M Share Offering at $3.50/sh
Aug 4, 2022 08:00AM Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
Aug 4, 2022 07:01AM Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed
Aug 4, 2022 07:00AM Poseida Therapeutics Announces Proposed Public Offering of Common Stock
Aug 3, 2022 05:02PM Form 8-K Cantor Fitzgerald Income For: Aug 01
Aug 3, 2022 04:01PM Poseida Therapeutics (PSTX) Announces Proposed Stock Offering, Size not Disclosed
Aug 3, 2022 04:01PM Poseida Therapeutics Announces Proposed Public Offering of Common Stock
Aug 3, 2022 06:15AM "We Encourage Investors to Acquire SPNE Shares" - Cantor Fitzgerald SeaSpine (SPNE) at Overweight with $21 Price Target
Aug 2, 2022 05:59AM UPDATE: Tilray (TLRY) PT Lowered to $4.15 at Cantor Fitzgerald
Jul 28, 2022 01:32PM Pfizer (PFE) Earnings Growth 'Underappreciated' - Cantor Fitzgerald
Jul 28, 2022 01:02PM UPDATE: Cantor Fitzgerald Downgrades ObsEva (OBSV) to Neutral
Jul 27, 2022 08:00AM Cantor Fitzgerald Income Trust, Inc. Closes $118 Million Dollars in Real Estate Related Acquisitions
Jul 26, 2022 09:14AM StoneX Group (SNEX) Launches Institutional Credit Offering in Asia
Jul 26, 2022 09:13AM StoneX Launches Institutional Credit Offering in Asia
Jul 20, 2022 05:50AM Cantor Fitzgerald Reiterates Overweight Rating, $215 Price Target on Johnson & Johnson (JNJ) Post Earnings
Jul 19, 2022 02:01PM Form 424B3 Cantor Fitzgerald Income
Jul 19, 2022 07:03AM UPDATE: Cantor Fitzgerald Assumes Arcturus Therapeutics (ARCT) at Overweight
Jul 19, 2022 06:02AM Form EFFECT Cantor Fitzgerald Income
Jul 19, 2022 05:58AM EYP-1901 Peak Sales Opportunity is Underappreciated - Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight
Jul 18, 2022 01:08PM Cantor Fitzgerald Launches Cantor Fitzgerald Sustainable Infrastructure Fund
Jul 15, 2022 06:55AM Cantor Fitzgerald Assumes Alaunos Therapeutics Inc. (TCRT) at Overweight
Jul 15, 2022 06:08AM Sanara MedTech (SMTI) PT Raised to $50 at Cantor Fitzgerald Post Accretive Scendia Acquisition, Encourage Investors to Acquire Undervalued Shares
Jul 14, 2022 12:05PM IDB BANK APPOINTS KENNETH SAVIO AS NEW CEO OF IDB CAPITAL
Jul 13, 2022 06:18PM Cantor Fitzgerald Downgrades ContraFect (CFRX) to Neutral, Lowers PT to $1 from $15
Jul 13, 2022 05:10PM Orchid Island Capital Announces Estimated Second Quarter 2022 Results, July 2022 Monthly Dividend and June 30, 2022 RMBS Portfolio Characteristics
Jul 13, 2022 05:03PM Form POS AM Cantor Fitzgerald Income
Jul 13, 2022 09:11AM Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Following Latest Nu.Q Data
Jul 13, 2022 07:44AM Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition
Jul 13, 2022 06:38AM UPDATE: Cantor Fitzgerald Downgrades Humanigen (HGEN) to Neutral
Jul 13, 2022 06:37AM UPDATE: Cantor Fitzgerald Starts BioMarin Pharmaceutical Inc. (BMRN) at Overweight
Jul 13, 2022 06:37AM UPDATE: Cantor Fitzgerald Starts Alnylam Pharmaceuticals (ALNY) at Neutral
Jul 13, 2022 06:36AM Latest Hutchinson (HCM) Data "Underscores Belief HCM's Pipeline is Underappreciated" - Cantor Fitzgerald Reiterates Overweight and $50 Price Target
Jul 12, 2022 01:43PM Form 424B3 CANTOR FITZGERALD SUSTAI
Jul 12, 2022 05:42AM Cantor Fitzgerald Starts Kura Oncology (KURA) at Overweight (CORRECTION)
Jul 11, 2022 08:35AM We Encourage Investors to Acquire Nyxoah SA (NYXH) Shares - Cantor Fitzgerald Bullish on Stock Following FDA Approval of ACCESS Trial
Jul 11, 2022 06:01AM UPDATE: Cantor Fitzgerald Starts Blucora Inc. (BCOR) at Overweight
Jul 8, 2022 05:01PM Form 8-K Cantor Fitzgerald Income For: Jul 05
Jul 8, 2022 02:09AM Investors fear earnings season will spark new equities selloff
View More Recent Stories View Older Stories